Business Context and Reporting Period
Revolution Medicines, Inc. (RVMD) filed a Form 8-K on April 30, 2021, to provide a Regulation FD disclosure regarding clinical trial updates. The company is an emerging growth company focused on oncology drug development.
Key Financial Metrics
This filing is a current report regarding clinical progress and does not contain financial statements. Consequently, data on revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Updates
- Study Update: The company provided an update on the Amgen-sponsored Phase 1b study (CodeBreak 101c) evaluating RMC-4630 in combination with sotorasib (AMG 510).
- Tolerability: Available data demonstrated acceptable tolerability and cleared early dose levels.
- Dosing Status: The study is currently dosing patients at the RMC-4630 target dose of 200 mg on a Day 1/Day 2 weekly schedule.
Guidance, Outlook, and Risks
- Timeline: The company expects the selection of a combination dose in the second half of 2021.
- Data Release: Clinical data from the combination therapy is not expected to be provided in 2021. Amgen, as the sponsor, will report data at a future date at its discretion.
- Risks: Forward-looking statements are subject to risks inherent in drug development, including early-stage development uncertainties, regulatory approval processes, manufacturing challenges, intellectual property protection, capital sufficiency, and the impact of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the specific dosing schedule (200 mg, Day 1/Day 2 weekly) for RMC-4630 in the CodeBreak 101c study.
- Confirm the timeline for the selection of the combination dose (expected H2 2021).
- Note that clinical data release is dependent on Amgen's discretion and is not expected in 2021.
- Review the company's Form 10-K filed on March 2, 2021, for detailed financial position and comprehensive risk factors.